ERS CONGRESS 2018

NTM Dialogue

CONTROVERSIES IN NTM LUNG DISEASE –
AN INTERACTIVE CASE DISCUSSION


18th September 2018
17:30 – 19:00 h
Room 7.3W

An NTM lung infection can be a chronic and progressive condition that targets patients who are already struggling with pre-existing lung conditions, such as bronchiectasis, COPD and previous TB. The sign and symptoms of NTM lung infections are so common and unspecific, it can be easily masked by those respiratory comorbidities. This may lead to NTM going untreated for months, even years.1-4


SPEAKERS:

Prof. Claire Andrejak

Prof. James Chalmers

Dr. Jakko van Ingen

INSMED IS COMMITTED TO NTM PATIENTS

There is a rise in the incidence of a rare lung infection that could be affecting your patients – nontuberculous mycobacteria, known as NTM.5 Among other underlying diseases – like patients with COPD or a previous TB – in particular patients with bronchiectasis are at high risk for NTM pulmonary infection.6 Finally NTM pulmonary infection can be a chronic and debilitating condition that is associated with high mortality rates.2,7,8

Insmed is a global, biopharmaceutical company whose mission is to transform the lives of patients with serious, rare diseases. To this end, we are dedicated to engaging pulmonary specialists in a discussion, and supporting medical education about who is most at risk, diagnosis and management of NTM lung infections.

VISIT US AT THE ERS INTERNATIONAL CONGRESS 2018

Please join us at the ERS International Congress 2018 in Paris/France, Saturday, 15 September through Wednesday, 19 September, where Insmed is pleased to collaborate with expert physicians to bring you an Evening Expert Forum on issues surrounding the diagnosis and management of NTM.

PLEASE VISIT US AT STAND #G.07
TO CONTINUE THE CONVERSATION.

References

  1. Young JD et al. Differentiating colonization from infection can be difficult. J Respir Dis. 2007;28(1):7-18.
  2. Griffith DE et al. on behalf of the ATS Mycobacterial Diseases Subcommittee. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416.
  3. Adjemian J et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185(8):881-886.
  4. Winthrop KL et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features. Am J Respir Crit Care Med. 2010;182(7):977-982.
  5. Loebinger MR and T Welte. Current perspectives in the Diagnosis and Treatment of Nontuberculous Mycobacterial Pulmonary Disease. European Respiratory & Pulmonary Diseases. 2016;2(2):54–57
  6. Andrejak C et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68:256-262
  7. Winthrop KL et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features. Am J Respir Crit Care Med. 2010;182(7):977-982.
  8. Diel R et al. Burden of non-tuberculous mycobacterial pulmonary disease in Germany. Eur Respir J. 2017;49(4). pii: 1602109. doi: 10.1183/13993003.02109-2016.